We aim to improve anti-ageing drug discovery, currently achieved through laborious and 29 lengthy longevity analysis. Recent studies demonstrated that the most accurate molecular 30 method to measure human age is based on CpG methylation profiles, as exemplified by 31 several epigenetics clocks that can accurately predict an individual's age. Here, we 32 developed CellAge, a new epigenetic clock that measures subtle ageing changes in primary 33 human cells in vitro. As such, it provides a unique tool to measure the effects of relatively 34 short pharmacological treatments on ageing. We validated our CellAge clock against known 35 longevity drugs such as rapamycin and trametinib. Moreover, we uncovered novel anti-36 ageing drugs, torin2 and Dactolisib (BEZ-235), demonstrating the value of our approach as a 37 screening and discovery platform for anti-ageing strategies. CellAge outperforms other 38 epigenetic clocks in measuring subtle ageing changes in primary human cells in culture. The 39 tested drug treatments reduced senescence and other ageing markers, further consolidating 40 our approach as a screening platform. Finally, we showed that the novel anti-ageing drugs 41 we uncovered in vitro, indeed increased longevity in vivo. Our method expands the scope of 42 CpG methylation profiling from measuring human chronological and biological age from 43 human samples in years, to accurately and rapidly detecting anti-ageing potential of drugs 44 using human cells in vitro, providing a novel accelerated discovery platform to test sought 45 after geroprotectors.
healthy ageing. To this end, we used normal human mammary fibroblasts (HMFs) from a healthy 21-
year old donor that we cultured from passage 10 to passage 20, which is before these cells reach
Having built a precise epigenetic clock that measures methylation changes during replicative ageing 157 of human primary cells in vitro, we tested if anti-ageing drug treatment of HMFs and HDFs 158 decelerated the CellAge clock. We chose an mTOR inhibitor, rapamycin, which is one of the most 159 robust and evolutionarily conserved anti-ageing drug targets 36 , and which mediates its effect through 160 down-regulation of S6K and Pol III, and up-regulation of autophagy 37, 38 . We chose relatively low 161 rapamycin concentration of 5nM that did not inhibit cell growth ( Supplementary Fig. 1a ) but 162 moderately downregulated mTOR signalling, as evidenced by decreased pS6K and p4E-BP 163 phosphorylation ( Supplementary Fig. 3 by the gradual decrease of predicted-actual passage from 16 to 20 weeks. The low dose rapamycin 170 treatment did not affect population doublings, confirming that the methylation changes were not a 171 reflection of proliferation inhibition or slowing of the cell cycle ( Supplementary Fig. 1 ). This is further 172 evidenced by comparing the predicted passage from the CellAge clock against cumulative 173 population doubling, showing rapamycin samples lie on a separate line to that of the control samples 174 ( Supplementary Fig. 2b,c) . Contrarily, rapamycin samples and controls differed to considerably 175 lesser extent when actual passage and cumulative population doublings are compared 176 ( Supplementary Fig. 2b,c) . Importantly, we observed a similar pattern for HMFs and HDFs (Fig. 2) ,
177
suggesting that the CellAge clock could be applicable to different cells, albeit calibration is required 178 for cells that reach senescence at different rates.
179
We then focused on HMFs to test another anti-ageing drug, trametinib 40 , an inhibitor of the 180 MEK/ERK signalling pathway, which we also applied in low concentration to avoid any effect on 181 growth and population doubling ( Supplementary Fig. 1 and Fig. 3 ). The CellAge clock analysis of 182 trametinib treatment showed clock deceleration for all three passages tested ( Fig. 2 
186
We tested Dactolisib/BEZ235, a dual ATP competitive PI3K and mTOR inhibitor, for which we again 187 optimised the dose of the treatment to obtain a reduction in signalling without significant proliferation 188 impairment, as shown by pS6K downstream target 4E-BP ( Supplementary Fig. 3 ).
complete inhibition of the mTOR pathway, we were interested in examining its effect on replicative CellAge clock suggests that torin2 is indeed a novel anti-ageing drug (Fig. 2) , its effect on ageing in 201 mammalian cell culture appears to be less pronounced than that of rapamycin. This is in line with 202 literature suggesting that a promising strategy to improve healthy ageing is the development of 203 inhibitors that are highly specific for mTORC1 or that target mTORC1 downstream effectors 204 separately 41 .
205
Next, we compared our anti-ageing drug screening results obtained by the CellAge clock with 206 analyses using Horvath's Multi-tissue and Skin and Blood clock, as well as the PhenoAge clock. The 207 clocks did not detect any significant effect of anti-ageing drug treatment ( Supplementary Fig. 4 ). The
208
Skin and Blood clock 26 was used recently to measure deceleration of ageing in primary 209 fibroblasts 14,28 , however the concentration of rapamycin used in our conditions was five times lower and cell area, and the treated cells appeared particularly 'youthful' (Fig. 3 
238
treated cells, showing their efficacy in delaying the senescence programme (Fig. 3b,c) . In addition,
239
the most frequently used senescent marker, senescent-associated β-galactosidase activity (SA-240 βgal), was significantly decreased upon anti-ageing drugs treatment with rapamycin and 241 Dactolisib/BEZ235, but not in cells treated with trametinib (Fig. 3b,c) . Another difference in 242 senescent markers was observed with interleukin-6 (IL-6), which is one of the most important 243 inflammatory cytokines and part of the senescent-associated secretory phenotype. IL-6 was 244 significantly reduced in aged cells upon rapamycin and Dactolisib/BEZ235 treatment but not in 245 trametinib treated cells (Fig. 3b,c) . This difference possibly stems from the overactivated RAS/ERK 246 pathway being a more prominent inducer of senescence than the overactivated mTOR/PI3K 247 pathway 47 , and hence corresponding inhibitors have different potency in inhibiting senescence.
248
Finally, we examined the nucleolus, an organelle dedicated to rRNA production and ribosomal 249 assembly, as it has recently emerged that maintenance of its structure, and low levels of nucleolar 250 methyltransferase fibrillarin, is a common denominator for major anti-ageing intervention from worms 251 to mice 48 . We observed that as a consequence of ageing, nucleoli in aged HMFs lose their defined discovery platform to be valuable for the discovery of strongly sought after anti-ageing drugs and 307 geroprotective strategies to improve healthy human ageing.
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